Duke Spine Outcome Study (DSOS)

NCT04217525•Duke University

Summary

The primary goal of this registry is to increase the knowledge about spine tumors and other spine disorders to guide appropriate management strategies for the future. This registry will include the review of medical records, data collection for health related quality of life questionnaires, and collected tissues and samples. The study will require obtaining spinal lesions (tumor, etc.), blood, and bone marrow samples (from non-lesional bone) from selected patients, which will be collected during your surgery.

Eligibility

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age between 18 and 85 years.
•Able to read and write local language at an elementary level.
•Diagnosis of primary or metastatic tumor of the spine ); or
•Infection of the spine; or
•Instability of the spine; or
•Injury of the spine.
•Accessibility for treatment and follow up.
•Patient consent obtained according to Duke institutional policy.
•Age between 18 and 85 years.
•Spine surgery to be performed at Duke University Medical Center (DUMC) under the auspices of the neurosurgery program.
+3 more criteria

Exclusion Criteria

•History of substance abuse (recreational drugs, alcohol) within 12 months prior to screening
•Is a prisoner.
•A disease or condition that would, in opinion of the investigator, preclude accurate evaluation
•(e.g. significant psychiatric disease), or that would impair the ability of the patient to receive protocol treatment or comply with protocol.
•Pregnant or breast feeding during the study period (women of child-bearing potential will require a negative serum pregnancy test within 30 days of enrollment).
•Active infection, or fever of unknown origin.
•Inflammatory bowel disease.
•Systemic lupus erythematosus.
•Rheumatoid arthritis, or other autoimmune disease.
•History of or active hematologic or bone marrow diseases, including but not limited to diagnosed lymphomas, leukemias, sickle cell or other anemias not associated with their current condition.
+3 more criteria

Locations (1)

Duke University Medical Center

Durham, North Carolina, United States

Key Dates

Start Date

December 3, 2019

Primary Completion Date

December 1, 2026

Completion Date

December 1, 2026

Last Updated

January 20, 2026

Enrollment

900

ESTIMATED participants

Conditions

Spinal TumorSpinal Disorder

Liquid Biopsy Following BBB Disruption Using Barrier Disrupting Fields in Patients Undergoing Spine Surgery

NCT07224451

Spinal Tumors

View study

RECRUITINGNA

Evaluating the Efficacy and Safety of Intra-wound Vancomycin Powder in High Risk Patients

NCT03839914

Spinal DeformityTrauma+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 20, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Duke Spine Outcome Study (DSOS)

Inclusion Criteria

Exclusion Criteria

Liquid Biopsy Following BBB Disruption Using Barrier Disrupting Fields in Patients Undergoing Spine Surgery

Evaluating the Efficacy and Safety of Intra-wound Vancomycin Powder in High Risk Patients

Delineation of Target Volume of Stereotactic Radiotherapy for Spinal Tumors

A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy

Study of SBRT Efficacy on Intra and Extra -Cranial Tumors or Metastasis in Pediatrics Population (SBRT Pediatrics)

The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma